Category: Sleep Disorders

Sleep Disorders

Alkermes Granted Orphan Drug Designations for Alixorexton in US, Europe

The investigational oral orexin 2 receptor agonist received designations from the FDA for idiopathic hypersomnia and the European Commission for narcolepsy.

Sleep Disorders

Which Patients Benefit Most from Tirzepatide for Obesity & OSA?

New research identifies a "strong response endotype" of patients who experience nearly double the sleep apnea improvement from tirzepatide.

Sleep Disorders

Beyond the Residual Sleepiness Puzzle: Advocating for the Treated OSA Patient With Residual Sleepiness

In this one-hour webinar, sleep physician-presenters explore how to better identify, assess, and manage residual EDS in 2026—moving beyond the AHI to focus on real-world functional outcomes, patient-reported symptoms, and emerging treatment strategies.

Breathing Disorders

Revisiting RIP

The shift to home sleep testing is forcing a rethink of how respiratory effort is captured, validated, and clinically applied.

Insomnia

A Surprising ‘Core Feature of Insomnia’ May Have Been Identified in New Prospective Cohort Study

Research using contactless at-home monitoring over eight weeks reveals a hallmark difference that distinguishes chronic insomnia patients from those without the condition.

Hypersomnias

Alkermes Reports Positive Phase 3 Results for LUMRYZ in Idiopathic Hypersomnia

The REVITALYZ study met its primary endpoint, demonstrating significant improvements in excessive daytime sleepiness for adults with idiopathic hypersomnia treated with once-nightly LUMRYZ.

Movement Disorders

Biofeedback Device Reduces Sleep Bruxism by 60% in Clinical Study

AesyBite Active demonstrated a statistically significant reduction in bruxism activity and improved orofacial pain in a study of 26 patients, supporting Aesyra’s push for FDA approval in 2026.

Circadian Rhythm Disorders

Drug Shows Promise for Reducing Excessive Sleepiness in Early Morning Shift Workers

A new clinical trial from Mass General Brigham found that a drug approved for other indications helped early morning shift workers with shift work disorder stay more alert.

Parasomnias

Teen Scholar Recognized for Research on Sleep Paralysis in Adolescents

Yanchen Wang is named among 300 scholars in the Regeneron Science Talent Search 2026 for her project investigating the characteristics and risk factors of the parasomnia.